-
Posted by
Two Blokes Jul 23 -
Filed in
Stock
-
10 views
$43Bn Seagen acquisition positions Pfizer to dominate the $140Bn antibody-drug conjugate market. Numerous potential blockbusters launching pre-2030 should strengthen its oncology portfolio to offse patent cliff impact. Pfizer's 7% yield is well-covered at an 85% FCF payout ratio with a committed dividend growth strategy.
